U.S FDA APPROVED DRUGS FROM 01-01-08 TO 31-12-08
Drug name Indication Date of Approval
2.Voglibose 0.2mg/0.3mg tablet 28-12-07
(Mouth dissolving )
For improvement of parantial hyperphemia in diabetes mellitus only.
When diet and/or excercise or oral hypoglycemic drug or insulin
preparation in addition to diet and or excercise do not result in
adequate glycemic control.
U.S. FDA APPROVED DRUGS DURING 2007
166. Voglibose disp tablet 0.2mg/0.3mg 20-11-07
As approved Type 1 and 2 diabetes when insulin alone cannot supress pstprandial blood sugar Management of postprandial hyperglycemia in diabetic mellitus patients.
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Voglibose Diabetes Takeda 20-10-2004
FIXED DOSE COMBINATIONS APPROVED BY DCG(I)
FROM JANUARY 1961 TILL NOVEMBER 2014
Name of Drug Indication Date of Approval
1.Voglibose 0.2mg + 13-07-2009
Metformin 500mg tablets
As 2nd line treatment of type II Diabetes mellitus when
diet, exceercise and the single agent do not result in
adequate glycemic control
2. Voglibose 0.3mg + 08-06-2010
Metformin SR 500mg tablet
As 2nd line treatment of type II Diabetes mellitus when
diet, exceercise and the single agent do not result in
adequate glycemic control
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Voglibose 0.2mg 13-07-2009
+ Metformin 500mg tablets
As 2nd line treatment of Type II Diabetes Mellitus when Diet, Excercise
and the single agent do not result in adequate Glycemic Control
2.Voglibose 0.2mg /03mg Tablet 28-12-2007
Mouth Dissolved
For Improvement of parentral Hyperphemia in Diabetes Mellitus only
when diet and/or excercise or oral hypoglycemic drug or insulin preparation
in addition to diet and or excercise do not result in adequate glycemic control
3.Voglibose Disp Tablet 0.2mg/0.3mg 20-11-2007
As approved
4.Voglibose 0.3mg 06-08-2010
+ Metformin SR 500mg
Addl.Higher Stgth
As approved